Patient | 1 | 2 | 3 |
---|---|---|---|
Age, years | 71 | 65 | 46 |
Sex | Male | Male | Female |
Race | Caucasian | Caucasian | Caucasian |
Tumor | Metastatic melanoma | Metastatic melanoma | Metastatic melanoma |
CPI | Anti-CTLA4 antibody | Anti-PD-1 antibody | Anti-PD-1 antibody |
Onset of arthritis-irAEs (days after initiation of CPI) | 100 | 19 | 49 |
Pattern of arthritis | Symmetric polyarthritis involving small joints | Symmetric polyarthritis involving small and large joints | Symmetric polyarthritis involving small joints |
History of autoimmune disease prior to CPI treatment | No | No | No, but known positive ANA |
Autoantibody results | ANA, CCP neg | ANA, CCP, RF neg | CCP, RF, Ro, dsDNA neg |
RF: 27 (UNL: 15.9) | ANA 1:640 (homogenous) | ||
La pos | |||
Discontinuation of CPI treatment due to arthritis-irAE | N/A | No | Yes |
Duration of anti-IL-6R antibody therapy, months | 12 | 15 | 3 |
Tumor response to CPI as of December 2016 (RECIST 1.1) | Complete remission | Progressive disease | Progressive disease |
CPI, immune checkpoint inhibitor; UNL, upper normal limit; ANA, antinuclear antibody; CCP, anti-cyclin citrullinated antibody; RF, rheumatoid factor; Ro, anti-SSA antibody; dsDNA, anti–double-stranded DNA antibody; La, anti-SSB antibody; N/A, not applicable.